Rigel Pharmaceuticals Completes $70M VEPPANU™ Licensing Agreement
Summary
Rigel Pharmaceuticals announced the completion of its exclusive global licensing agreement for VEPPANU™ (vepdegestrant), involving a $70 million upfront payment.
Key Events
-
Licensing Agreement Completed
Rigel Pharmaceuticals has completed its exclusive global licensing agreement for VEPPANU™ (vepdegestrant) with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
-
$70 Million Upfront Payment Made
The company made a one-time upfront payment of $70.0 million in connection with the completion of the agreement.
-
Acquisition of Worldwide Rights
Rigel now holds exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU™, a significant addition to its product pipeline.
Analysis
This 8-K confirms the finalization of the previously announced exclusive global licensing agreement for VEPPANU™ (vepdegestrant). The completion of this significant transaction, involving a $70 million upfront payment, solidifies Rigel's acquisition of worldwide rights to a key asset, impacting its product pipeline and financial position. This follows the initial announcement of the agreement on May 12, 2026.
At the time of this filing, RIGL was trading at $33.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $617.4M. The 52-week trading range was $18.14 to $52.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.